MENU
+Compare
RENB
Stock ticker: NASDAQ
AS OF
Apr 17 closing price
Price
$0.35
Change
-$0.01 (-2.78%)
Capitalization
57.26M

RENB Renovaro Forecast, Technical & Fundamental Analysis

Renovaro Inc is a biopharmaceutical company... Show more

RENB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RENB with price predictions
Apr 16, 2025

RENB's RSI Indicator is staying in oversold zone for 13 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RENB advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

RENB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RENB as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

RENB moved below its 50-day moving average on March 13, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RENB crossed bearishly below the 50-day moving average on March 18, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RENB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RENB entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RENB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.698) is normal, around the industry mean (13.662). P/E Ratio (0.000) is within average values for comparable stocks, (62.714). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (248.452).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RENB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RENB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a financial conglomerate

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Financial Conglomerates
Address
2080 Century Park East
Phone
+1 305 918-1980
Employees
12
Web
https://www.enochianbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X84895.750000861.882800
+1.03%
Bitcoin cryptocurrency
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

RENB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RENB has been loosely correlated with DTIL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RENB jumps, then DTIL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RENB
1D Price
Change %
RENB100%
-2.06%
DTIL - RENB
36%
Loosely correlated
+0.20%
TNGX - RENB
30%
Poorly correlated
+0.78%
XBIT - RENB
26%
Poorly correlated
-0.68%
QRON - RENB
25%
Poorly correlated
N/A
BRCTF - RENB
25%
Poorly correlated
N/A
More